Outcome of Board Meeting held on Thursday, 12th February, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Decipher Labs Ltd's board, at its meeting on February 12, 2026, approved the unaudited financial results for Q3 and the nine months ended December 31, 2025, along with the limited review report. On a consolidated basis, revenue from operations fell sharply to ₹1,045 lakhs for 9M FY26 from ₹1,911.24 lakhs in 9M FY25, a decline of roughly 45%, while Q3 revenue dropped to ₹321.26 lakhs from ₹580.47 lakhs YoY. The company deepened its losses, posting a consolidated net loss of ₹394.54 lakhs for 9M FY26 versus a ₹57.41 lakh loss a year ago, with Q3 loss at ₹53.88 lakhs. Standalone results were even weaker, with 9M revenue plummeting to ₹106.85 lakhs (from ₹627.72 lakhs) and a small loss of ₹8.57 lakhs. The pharma manufacturing and trading segment reported zero revenue in Q3 FY26, with virtually all business now coming from the consultancy services segment and its US and Bahrain subsidiaries.
Sharply falling revenues and widening losses, particularly at the consolidated level driven by overseas subsidiaries, signal continued operational stress and are likely to weigh negatively on the stock. Investors should watch for signs of revenue stabilisation and a credible path back to profitability in the coming quarters.